Read More

Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma’s Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial

During the R&D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or proopiomelanocortin (POMC) or leptin recep

RYTM

Read More

Turnaround For Pharvaris Since FDA Clinical Hold – Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks

Pharvaris NV (NASDAQ: PHVS) released topline data from the CHAPTER-1 Phase 2 study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful results as an oral preventative treatment for people living with 

PHVS

Read More

“Senators Launch Bipartisan Probe Of Private Equity’s Growing Role In U.S. Health Care; ‘When It Comes To Our Nation’s Hospitals, A Business Model That Prioritizes Profits Over Patient Care And Safety Is Unacceptable,’ Said Sen. Chuck Grassley” – NBC N…

https://www.nbcnews.com/politics/congress/senators-grassley-whitehouse-probe-private-equity-us-health-care-rcna128070 Two U.S. senators have launched a bipartisan investigation into secretive and powerful

SPY